Monday, October 26, 2026 · Daily editionET --:--:--

Finished

Exoskeleton Gait Training in Guillain-Barré Syndrome: Safety, Feasibility, Usability, and Longitudinal Outcomes

NCT07556809 · Institut Guttmann · Updated 8 May 2026

What is being tested
Exoskeleton Wandercraft Atalante X, usability and gait rehabilitation
For
Guillain Barré Syndrome
Kind of study
Tests a treatment or device on volunteers. No drug phase (a device or procedure study).
Who can join
Ages 18 years to 75 years. About 11 people. The full rules are on the registry page.
Where
Spain
When
Starts or started 7 Aug 2023, ends 12 Dec 2025. Registered 29 April 2026.
Results
None posted yet.

In the researchers' words

The main objective of the study is to determine if the Atalante X exoskeleton by Wandercraft is a safe, reliable, and usable device for people with Guillain-Barré Syndrome (GBS) who are unable to walk. The secondary objective is to assess the impact of using this device on the gait and functional recovery of this type of users (GBS). The users undergo 20 training sessions over 6 weeks. Assessments are carried out at baseline, post-intervention, and at a 4-week follow-up after completing the training sessions. In all assessments, the same outcomes is conducted using the Medical Research Council Outcome, 10-Meter Walk Test, 6-Minute Walking Test, Kansas University Standing Balance Scale, Functional Independence Measure and Level of Assistence. To assess satisfaction, the QUEST 2.0 scale is administered. During this 20 sessions, monitoring is conducted for possible adverse effects that may appear and for the time required for donning and doffing the device.
ClinicalTrials.gov, NCT07556809

Sites

  • Institut GuttmannBadalona, Barcelona, Spain